Boston Scientific is categorized as a medical device company.
Source Post
The Most Obvious Buys in This Market Right Now
Jun 19, 2026
The creator highlights healthcare as a potentially overlooked sector compared to the heavily favored technology and semiconductor industries. Despite some individual healthcare stocks performing well, the sector as a whole, represented by the ETF XLV, has lagged the S&P 500 significantly over multiple years. This underperformance, coupled with strong growth in areas like GLP-1 drugs from companies like Eli Lilly and Novo Nordisk, suggests potential opportunities for investors seeking less crowded trades, provided valuations are considered.
Linked Mentions
Tickers discussed in this post
Bristol Myers is categorized as a pharmaceutical stock with valuation as a primary focus.
Pfizer is listed as a pharmaceutical stock where valuation is a key consideration.
Gilead is noted as a pharmaceutical stock with valuation considerations.
Amgen is mentioned as a pharmaceutical stock with valuation considerations.
AbbVie is noted as an income-compounding stock within the healthcare sector.
Novo Nordisk is highlighted as a major growth story in the market due to its GLP-1 drugs, but valuation needs to be considered.
Eli Lilly is highlighted as a major growth story in the market due to its GLP-1 drugs, but valuation needs to be considered.
Zoetis is mentioned as a healthcare stock that has been hit hard.
Medtronic is mentioned as a healthcare stock that has been hit hard.
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.